CORPUS CHRISTI, Texas, Dec. 14, 2005 (PRIMEZONE) -- CSMG Technologies, Inc. (OTCBB:CTUM) announced today that over 5,000 successful surgeries have now been performed using patented tissue bonding/welding technology licensed by the company. The surgeries have been performed by doctors in the Ukraine in nearly 70 different approved surgical procedures.
Use of the tissue welding technology in Ukraine is successfully growing as the medical facility continues to develop new, unique methods of post-traumatic recovery and preservation of vitality in organs that previously were believed to be inoperable.
Don Robbins, CEO of CSMG Technologies, said, "This is important further evidence of the validity of the tissue bonding/welding technology that we have licensed. Our patented bonding/welding procedures are almost bloodless and completed in less time than conventional surgeries. We are very happy with the progress we are making and the enormous benefit we have brought to our patients. We believe this radio frequency fusion technology, which does not use staples, sutures, glues or sealant, will lead to a new age for surgical procedures and faster healing of soft biological tissues."
About CTUM's Tissue Bonding Technology
CTUM's patented tissue welding/bonding device bonds through radio frequency fusion and reconnects living soft biological tissue (organs) without the use of foreign matter or conventional wound-closing devices such as sutures, staples, sealant or glues. The technology leaves little or no scar visible to the naked eye after a few months. Unlike other tissue coagulation methods that tend to destroy tissue by charring, searing and necrosis, the CTUM-patented technology bonds and reconnects incised tissue and avoids this by using a patented low-heat delivery method aimed at restoration of the normal functions of the live organs and tissue. U.S. and Australia patents have been issued with other U.S. and foreign patents pending.
In Ukraine, more than 5,000 successful human surgeries in clinical trials have been completed on various organs using a number of types of procedures. Surgeons at four Ukraine hospitals and clinics are using the tissue bonding technology in clinical trials and are performing open and laparoscopic surgical procedures.
CTUM owns the technology and exclusive world rights to the medical device through Live Tissue Connect, Inc., a subsidiary corporation formed for the development and exploitation of the platform technology. The technology, owned by CTUM, was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine at Kiev, Ukraine, headed by Professor B.E. Paton.
CTUM maintains offices in Corpus Christi, Texas, Washington D.C., Atlanta, Ga., and Kiev, Ukraine.
A profile for investors may be found at http://www.hawkassociates.com/csmg/profile.htm.
Additional information about CSMG can be found at http://www.ctum.com or e-mail publicrelations@ctum.com. An online investor kit containing CSMG press releases, SEC filings, current Level II price quotes, interactive Java, stock charts and other useful information for investors can be found at http://www.hawkassociates.com and http://www.americanmicrocaps.com.
Investors may contact Don Robbins or K. Bruce Jones, CSMG, at (361) 887-7546, e-mail: publicrelations@ctum.com, or Frank Hawkins or Julie Marshall, Hawk Associates, at (305) 451-1888, e-mail: info@hawkassociates.com.
Safe-Harbor Statement: Under the Private Securities Litigation Reform Act of 1995. This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.